• 1
    Beral V, Banks E, Reeves G, Appleby PN. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4: 191215.
  • 2
    The Million Women Study Collaborative GroupThe Million Women Study: design and characteristics of the study population. Breast Cancer Res 1999;1: 7380.
  • 3
    British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. London : BMJ Books and Wallingford: Pharmaceutical Press, 1999: 37.
  • 4
    Townsend P, Phillimore P, Beattie A. Health and Deprivation: Inequality and the North. London : Croom Helm, 1988.
  • 5
    Statacorp. Stata Statistical Software: Release 5.0. College Station , Texas : Stata, 1997.
  • 6
    Banks E, Beral V, Cameron R, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 2001;6: 357363.
  • 7
    Banks E, Beral V, Cameron R, et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Res 2002;4: R1.1R1.6.
  • 8
    Office for National Statistics. Key Health Statistics from General Practice 1998. Series MB6 (No. 2). London: National Statistics, 2000.
  • 9
    Sinclair HK, Bond CM, Taylor RJ. Hormone replacement therapy: a study of women's knowledge and attitudes. Br J Gen Pract 1993;43: 365370.
  • 10
    Spector TD. Use of oestrogen replacement therapy in high risk groups in the United Kingdom. BMJ 1989;299: 14341435.
  • 11
    Lancaster T, Surman G, Lawrence M, et al. Hormone replacement therapy: characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records. J Epidemiol Community Health 1995;49: 389394.
  • 12
    Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137: 11251135.
  • 13
    Moorhead T, Hannaford P, Warskyi M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol 1997;104: 290297.
  • 14
    Lawrence M, Jones L, Lancaster T, Daly E, Banks E. Hormone replacement therapy: patterns of use studied through British general practice computerized records. Fam Pract 1999;16: 335342.
  • 15
    Kuh DL, Wadsworth M, Hardy R. Women's health in midlife: the influence of the menopause, social factors and health in earlier life. Br J Obstet Gynaecol 1997;104: 923933.
  • 16
    Barrett Connor E, Brown WV, Turner J, Austin M, Criqui MH. Heart disease risk factors and hormone use in postmenopausal women. JAMA 1979;241: 21672169.
  • 17
    Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328: 10691075.
  • 18
    Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers?. Am J Epidemiol 1996;143: 971978.
  • 19
    Rodstom K, Bengtsson C, Lissner L, Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenberg, Sweden. BMJ 1999;319: 890893.
  • 20
    Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Ethnic differences in use of hormone replacement therapy: community based survey. BMJ 1999;319: 610611.
  • 21
    Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health 1990;80: 12661268.
  • 22
    Maniolo TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993;88: 21632171.